RavenQuest Acquires Majority Stake in 1 Life Cannabis Corp.
03 1월 2019 - 8:00PM
RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) –
(CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) is pleased to
announce it has acquired a 51% interest in Abbotsford, British
Columbia based 1 Life Cannabis Corporation (“1 Life”).
1 Life has deep roots in the craft cannabis
community and focuses on premium, small batch artisan cannabis
cultivation. 1 Life will use RavenQuest’s 24,000 square foot
facility design which will become part of a license extension from
RavenQuest’s Health Canada license. 1 Life has submitted
plans to Health Canada which will include a large centralized
extraction and processing facility as well as multiple small grow
rooms ideal for unique, artisan growers to come together under one
roof.
RavenQuest CEO, George Robinson, stated that,
“It’s clear to us that there is a significant market for high
quality, premium artisan offerings. Premium cannabis almost
always comes from small batch, precision controlled indoor
facilities. As is the case with the alcohol market, there is
a lot of demand for boutique brands with unique
characteristics. Adding 1 Life underscores RavenQuest’s
continued commitment to becoming a central curator for high quality
artisan cannabis, particularly from British Columbia where there is
a rich history of premium micro-cultivation.”
“Being a consulting client of RavenQuest, 1
Life’s facility will be a RavenQuest design; their deep cultivation
knowledge and unique genetics are a great complement for
RavenQuest’s Orbital Garden technology,” Robinson continued.
1 Life CEO, Matt Fraser, stated, “We couldn’t be
happier with our new licensed producer partner as we endeavour to
produce artisan cannabis that is of the highest possible
quality. RavenQuest’s facility design and Orbital Garden
technology are absolutely world class. The precision control
of their grow methodologies is a perfect fit for the high standards
of our craft master growers.”
Under the terms of the transaction, RavenQuest
will acquire a controlling interest (51%) in 1 Life for $1.
This interest can be redeemed by 1 Life at any time after it
receives a license to produce under the Cannabis Act, and in
consideration RavenQuest will be granted an ongoing royalty of 15%
of the gross revenue from production at 1 Life. Completion of
the transaction with 1 Life is subject to completion of due
diligence, the negotiation of definitive documentation and the
receipt of any required regulatory approvals.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly
traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized
research & development. RavenQuest is a licensed producer
with facilities located in Markham, Ontario and Edmonton,
Alberta. RavenQuest maintains a research partnership with
Montreal’s McGill University focused upon cultivar (strain)
recognition, plant stabilization and yield maximization of the
cannabis plant. The Company focuses on partnerships with
Indigenous communities.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
“George Robinson” Chief Executive Officer
For further information, please contact: Mathieu
McDonald, Corporate Communications – 604-484-1230
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding Forward-Looking
Statements
All statements in this press release, other than
statements of historical fact, are “forward-looking information”
with respect to the Company within the meaning of applicable
securities laws, including statements with respect to the approval
and development of 1 Life’s licensed cannabis production and
processing facility, RavenQuest becoming a central curator for high
quality artisan cannabis, the grant to RavenQuest by 1 Life of a
15% royalty and the development of partnerships with Indigenous
communities. The Company provides forward-looking statements
for the purpose of conveying information about current expectations
and plans relating to the future and readers are cautioned that
such statements may not be appropriate for other purposes. By its
nature, this information is subject to inherent risks and
uncertainties that may be general or specific and which give rise
to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct and that objectives, strategic goals
and priorities will not be achieved. These risks and uncertainties
include but are not limited to those identified and reported in the
Company’s public filings under the Company’s SEDAR profile at
www.sedar.com. Although the Company has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking information, there may be other factors that cause
actions, events or results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
The Company disclaims any intention or obligation to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise unless required by law.
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025